obesity novo nordisk - Search News

Novo Nordisk Shares Fall

Reuters on MSN · 3d

Novo Nordisk's new obesity drug trial data disappoints again

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

Barron's on MSN · 1d

Novo Nordisk Is Falling. Compeitition Is a Killer.

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

The Wall Street Journal on MSN · 3d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Novo Nordisk Skeptic Finally Upgrades Stock

Seeking Alpha · 1h

Novo Nordisk: Stock Plunges, But It May Be Time To Load Up

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded manufacturing capacity remain strong. Read more on NVO stock here.

Markets Insider · 21h

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Bloomberg L.P. · 1d

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

2h

Novo Nordisk foundation’s obesity head works as paid adviser to chocolate maker Ferrero

Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...

Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

18h

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Medical Dialogues6h

CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results